Month: August 2023

Key highlights:Second quarter adjusted EBITDA improved by $1.2 million to $453,947, first profitable second quarter since 2019 Second quarter revenue down 8.2% year-over-year to $18.8 million Gross margin improved 377 basis points to 25.4% SG&A declined by 271 basis points to 24.2% $1.3 million in positive cash flow from operations, an improvement of $1.7 million compared to Q2 2022BONITA SPRINGS, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) — Innovative Food Holdings, Inc. (OTCQB: IVFH) (“IVFH” or the “Company”), a national seller of gourmet specialty foods to professional chefs and home gourmets, today reported its financial results for the second quarter of 2023. “During the second quarter, our revenue declined by 8.2%. Both our eCommerce and Specialty Foodservice businesses contributed to the declines, though both declined...

Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on track for data readouts in 2H 2023 NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2023. “In the second quarter we continued to advance our programs across Galactosemia, SORD Deficiency and Diabetic...

Completes realizations and closes first continuation vehicle All amounts in U.S. dollars unless otherwise stated TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the second quarter and six months ended June 30, 2023. “We continue to make steady progress on our strategic objectives,” said Bobby Le Blanc, Chief Executive Officer. “In the last few months, we have successfully realized several investments, closed our first continuation vehicle, and taken measured steps to reduce our cost structure and drive more consistent profitable growth. Together with our strong liquidity, we are well positioned to capitalize on the organic and inorganic opportunities before us.” Financial Results(unaudited)($ millions except per share amounts) Three Months Ended Six Months Ended...

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by 1Q 2024 Enrolling patients in monotherapy and combination arms of IMC-F106C in Phase 1/2 trial, including expansions in melanoma, NSCLC, endometrial, and ovarian cancers; data expected in 1H 2024 Cash and cash equivalents increased to £342 million ($435 million) as of June 30, 2023 Conference call today, August 10th at 8:00 AM EDT, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 August 2023) Immunocore Holdings...

Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endometrial and cervical cancers First patient dosed in Phase 1 study of CLN-978 in relapsed/refractory (R/R) B Cell non-Hodgkin lymphoma (B-NHL) Cash and investment position of $512.1 million as of June 30, 2023 continues to provide runway into 2026 CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended...

Prudent Use of Capital Generates Results: Gross Profit Climbs 168% High Level of Consistent Execution Key Differentiator for the Company Reaffirms Target of Positive Quarterly Cash Flow from Operations before Year-End Conference Call to Be Held Today at 8:00 AM ET. BELVIDERE, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three months ended June 30, 2023. Mr. Jim Kras, Chief Executive Officer of Edible Garden, stated, “We are excited to report record year-over-year revenue growth of 41.4% for the second quarter of 2023. Edible Garden has always stood out for its consistently...

Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the second quarter ended June 30, 2023, and provided an update on its pipeline programs. “With our pivotal Phase 3 study, Synpheny-3, now underway, we are focused on trial execution and ensuring access, inclusion and an optimal experience for the patients who participate in this landmark study of a potential breakthrough in the management of PKU,” said Aoife Brennan, M.B. Ch.B., Synlogic President...

Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023 (single-ascending dose) and October/November 2023 (multiple-ascending dose)Phase 2 proof-of-concept data for batoclimab in Graves’ disease (GD) expected in the fourth quarter of 2023Global clinical trials of batoclimab are ongoing in myasthenia gravis (MG), thyroid eye disease (TED), and chronic inflammatory demyelinating polyneuropathy (CIDP)NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2023. “Our strategic priority this past quarter was to advance our robust clinical programs. To that end, we are pleased...

Graf-Pak acquisition now integrated into the Lachine folding carton hub MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) — Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, today announced its results for the second quarter ended June 30, 2023. The Company will hold a conference call to discuss these results, today at 10:00 a.m. (Eastern Time). Second Quarter Financial Highlights and Recent EventsTotal revenue increased by 14.6% to $71.7 million, from $62.5 million in the second quarter of 2022. Envelope segment revenue up 7.3% to $49.3 million, from $45.9 million in the prior year. Packaging and specialty products segment revenue of $22.4 million, up 34.7% from $16.6 million last year. Net earnings were $2.1...